Quantinno Capital Management LP Has $57.49 Million Stock Position in Elevance Health, Inc. $ELV

Quantinno Capital Management LP lifted its stake in shares of Elevance Health, Inc. (NYSE:ELV) by 144.0% during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 196,369 shares of the company’s stock after purchasing an additional 115,886 shares during the quarter. Quantinno Capital Management LP’s holdings in Elevance Health were worth $57,487,000 at the end of the most recent reporting period.

Several other large investors also recently made changes to their positions in ELV. Kemnay Advisory Services Inc. bought a new stake in Elevance Health in the 4th quarter valued at about $31,000. J.Safra Asset Management Corp bought a new position in Elevance Health in the fourth quarter worth approximately $32,000. WealthCollab LLC grew its stake in Elevance Health by 42.2% in the first quarter. WealthCollab LLC now owns 91 shares of the company’s stock valued at $27,000 after acquiring an additional 27 shares during the period. ORG Partners LLC grew its stake in Elevance Health by 120.4% in the fourth quarter. ORG Partners LLC now owns 108 shares of the company’s stock valued at $38,000 after acquiring an additional 59 shares during the period. Finally, Dorato Capital Management bought a new stake in shares of Elevance Health during the fourth quarter valued at approximately $41,000. 89.24% of the stock is currently owned by institutional investors and hedge funds.

Key Elevance Health News

Here are the key news stories impacting Elevance Health this week:

• Positive Sentiment: Zacks Research raised multiple earnings estimates. The firm increased its FY2026 EPS forecast to $27.06 from $26.79, FY2027 to $28.83 from $28.51, and FY2028 to $32.49 from $31.77. It also raised estimates for Q2 2027, Q4 2027, Q1 2028 and Q2 2028, indicating improving expectations for Elevance Health’s longer-term profitability.
• Positive Sentiment: Insider buying provided a vote of confidence. A report highlighted purchases of Elevance Health shares by the company’s CEO and chairman, a potentially supportive signal because insider buying can suggest management views the stock as undervalued. Elevance Health Pick of the Week at Smart Insider Following CEO, Chairman Share Purchases
• Neutral Sentiment: Peer comparison offers limited direct impact. A head-to-head survey compared Elevance Health with Aeon Global Health, but the article does not indicate a material change to ELV’s earnings outlook or valuation. Head to Head Survey: Elevance Health and Aeon Global Health
• Negative Sentiment: Analyst commentary remains cautious. A Seeking Alpha analysis said Elevance Health has upside potential but is “not yet a buy,” which may limit buying interest. Investors may also be focused on near-term earnings pressure: the latest quarterly EPS of $7.45 exceeded estimates but declined from $8.84 in the prior-year period. Elevance Health Has Upside, But Not Yet A Buy

Wall Street Analysts Forecast Growth

A number of equities analysts recently issued reports on the company. Weiss Ratings upgraded Elevance Health from a “hold (c-)” rating to a “hold (c)” rating in a report on Monday, May 18th. Deutsche Bank Aktiengesellschaft upgraded shares of Elevance Health from a “hold” rating to a “buy” rating and upped their price objective for the stock from $363.00 to $498.00 in a report on Wednesday, May 20th. Bank of America raised their price objective on shares of Elevance Health from $435.00 to $460.00 and gave the company a “buy” rating in a research note on Thursday, June 4th. Evercore reiterated a “hold” rating on shares of Elevance Health in a report on Tuesday, May 19th. Finally, Cantor Fitzgerald upped their target price on shares of Elevance Health from $400.00 to $450.00 and gave the stock an “overweight” rating in a report on Tuesday, July 7th. Fifteen investment analysts have rated the stock with a Buy rating and eight have given a Hold rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $440.90.

Insider Buying and Selling at Elevance Health

In other Elevance Health news, Director Robert L. Dixon, Jr. sold 151 shares of the company’s stock in a transaction dated Thursday, June 11th. The shares were sold at an average price of $401.77, for a total transaction of $60,667.27. Following the sale, the director directly owned 10,734 shares of the company’s stock, valued at $4,312,599.18. This represents a 1.39% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Insiders own 0.34% of the company’s stock.

Elevance Health Trading Down 2.5%

Shares of Elevance Health stock opened at $376.21 on Thursday. The company has a market capitalization of $81.59 billion, a P/E ratio of 16.72, a price-to-earnings-growth ratio of 2.22 and a beta of 0.67. The stock has a fifty day simple moving average of $397.65 and a 200 day simple moving average of $356.66. Elevance Health, Inc. has a 12-month low of $273.71 and a 12-month high of $436.24. The company has a current ratio of 1.52, a quick ratio of 1.52 and a debt-to-equity ratio of 0.68.

Elevance Health (NYSE:ELV) last issued its quarterly earnings data on Wednesday, July 15th. The company reported $7.45 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $6.21 by $1.24. The business had revenue of $49.83 billion during the quarter, compared to the consensus estimate of $48.88 billion. Elevance Health had a net margin of 2.47% and a return on equity of 14.64%. The firm’s quarterly revenue was up .8% compared to the same quarter last year. During the same period in the prior year, the firm posted $8.84 EPS. On average, sell-side analysts anticipate that Elevance Health, Inc. will post 27.04 earnings per share for the current fiscal year.

Elevance Health Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, September 25th. Stockholders of record on Thursday, September 10th will be given a dividend of $1.72 per share. This represents a $6.88 dividend on an annualized basis and a dividend yield of 1.8%. The ex-dividend date of this dividend is Thursday, September 10th. Elevance Health’s dividend payout ratio is currently 30.58%.

Elevance Health Profile

Elevance Health, Inc (NYSE: ELV) is a large U.S.-based health benefits company that provides a broad range of health insurance products and related services. Headquartered in Indianapolis, the company rebranded from Anthem, Inc to Elevance Health in 2022 while continuing to operate consumer-facing health plans under established state and national brands. Gail Boudreaux serves as chief executive officer and president, leading the company’s strategic focus on integrated health care and benefit delivery.

Elevance’s core activities include offering medical and specialty health plans for individuals, employers and government programs, including Medicare and Medicaid managed-care products.